LILRB5; LIR8; Leukocyte immunoglobulin-like receptor subfamily B member 5; CD85 antigen-like family member C; Leukocyte immunoglobulin-like receptor 8; LIR-8; CD85c
Application:
WB,IHC-p,ELISA
Reactivity:
Human
Immunogen:
The antiserum was produced against synthesized peptide derived from the N-terminal region of human LILRB5. AA range:21-70
Formulation:
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source:
Rabbit
Dilution:
Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications.
Other NameLILRB5; LIR8; Leukocyte immunoglobulin-like receptor subfamily B member 5; CD85 antigen-like family member C; Leukocyte immunoglobulin-like receptor 8; LIR-8; CD85c
ApplicationWB,IHC-p,ELISA
ReactivityHuman
ImmunogenThe antiserum was produced against synthesized peptide derived from the N-terminal region of human LILRB5. AA range:21-70
FormulationLiquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
SourceRabbit
DilutionWestern Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications.